Blood‐based markers (BBMs) have recently shown promise to revolutionize the diagnostic
and prognostic work‐up of Alzheimer's disease (AD), as well as to improve the design of …

Timely detection of the pathophysiological changes and cognitive impairment caused by
Alzheimer's disease (AD) is increasingly pressing because of the advent of biomarker …

Blood biomarkers indicating elevated amyloid-β (Aβ) pathology in preclinical Alzheimer's
disease are needed to facilitate the initial screening process of participants in disease …

Well-authenticated biomarkers can provide critical insights into the biological basis of
Alzheimer disease (AD) to enable timely and accurate diagnosis, estimate future burden and …

Blood biomarkers have been considered tools for the diagnosis, prognosis, and monitoring
of Alzheimer's disease (AD). Although amyloid-β peptide (Aβ) and tau are primarily blood …

As the leading cause of dementia, Alzheimer's disease (AD) is a major burden on affected
individuals, their families and caregivers, and healthcare systems. Although AD can be …

Alzheimer's disease (AD) is a complex, progressive primary neurodegenerative disease.
Since pivotal genetic studies in 1993, the ε4 allele of the apolipoprotein E gene (APOE ε4) …

Introduction Plasma amyloid beta (Aβ) 1‐42/Aβ1‐40 ratio, phosphorylated‐tau181 (p‐
tau181), glial fibrillary acidic protein (GFAP), and neurofilament light (NfL) are putative blood …

Staging the severity of Alzheimer's disease pathology using biomarkers is useful for
therapeutic trials and clinical prognosis. Disease staging with amyloid and tau PET has face …

Over the past several years, there has been a surge in blood biomarker studies examining
the value of plasma or serum neurofilament light (NfL) as a biomarker of neurodegeneration …